{
    "clinical_study": {
        "@rank": "46972", 
        "arm_group": {
            "arm_group_label": "Voglibose 0.2 mg or OD Tablets 0.2 mg", 
            "description": "Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal."
        }, 
        "brief_summary": {
            "textblock": "To determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent\n      progression to type 2 diabetes mellitus in patients with impaired glucose tolerance in the\n      routine clinical setting."
        }, 
        "brief_title": "Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance \"Long-term Use in Patients With Impaired Glucose Tolerance\"", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Impaired Glucose Tolerance", 
        "condition_browse": {
            "mesh_term": "Glucose Intolerance"
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of Voglibose (Basen) designed to\n      determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent\n      progression to type 2 diabetes mellitus in patients with impaired glucose tolerance in the\n      routine clinical setting.\n\n      Subjects will be patients with impaired glucose tolerance. The planned sample size is 1,000.\n\n      The usual adult dosage is 0.2 mg of voglibose administered orally three times daily\n      immediately before each meal."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must meet all of the following criteria ([1] to [3]) to be included in this\n             study:\n\n               1. Determined as having IGT (defined as fasting blood glucose < 126 mg/dL and\n                  2-hour post 75-g oral glucose tolerance test [OGTT] blood glucose of 140-199\n                  mg/dL) without improvement despite treatment with diet therapy and exercise\n                  therapy for 3-6 months\n\n               2. Meets any of the following conditions:\n\n                  (i) Concurrently has hypertension*1 (ii) Concurrently has dyslipidemia*2 (iii)\n                  Is obese (BMI \u226525 kg/m2) (iv) Has a family history of diabetes mellitus in\n                  relatives to the second degree as defined by Japanese law*3\n\n               3. Regularly visits the study site and can be observed for 72 weeks\n\n                    -  1: Hypertension: Patients with systolic blood pressure \u2265 140 mmHg or\n                       diastolic blood pressure \u2265 90 mmHg, or patients on oral antihypertensive\n                       medication.\n\n                    -  2: Dyslipidaemia: Patients with any of the following conditions or patients\n                       on oral antidyslipidemic medication\n\n          -  Hyper LDL cholesterolemia (fasting LDL-cholesterol \u2265140 mg/dL)\n\n          -  Hypo HDL cholesterolemia (fasting HDL-cholesterol < 40 mg/dL)\n\n          -  Hypertriglyceridemia (fasting triglyceride \u2265150 mg/dL) *3: Relatives to the second\n             degree of consanguinity refer to blood relatives who are the subject's \"father or\n             mother, grandfather or grandmother, brothers or sisters, children, or grandchildren.\"\n             Note that these do not include spouse's relatives.\n\n        Exclusion Criteria:\n\n          -  Patients meeting either of the following criteria ([1] or [2]) will be excluded:\n\n               1. Previously diagnosed with diabetes mellitus\n\n               2. Has any contraindications to Basen as specified below:\n\n                  (i) Severe ketosis, diabetic coma or precoma (ii) Severe infection,\n                  perioperative state, or serious trauma (iii) History of hypersensitivity to any\n                  ingredients of Basen"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with impaired glucose tolerance"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993927", 
            "org_study_id": "340-012", 
            "secondary_id": "JapicCTI-132304"
        }, 
        "intervention": {
            "arm_group_label": "Voglibose 0.2 mg or OD Tablets 0.2 mg", 
            "description": "Voglibose Tablets / Voglibose OD Tablets", 
            "intervention_name": "Voglibose", 
            "intervention_type": "Drug", 
            "other_name": "Basen Tablets, AO-128"
        }, 
        "intervention_browse": {
            "mesh_term": "Voglibose"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug Therapy", 
        "lastchanged_date": "November 19, 2013", 
        "number_of_groups": "1", 
        "official_title": "Basen Tablets 0.2 / Basen Oral Disintegrant\uff08OD\uff09 Tablets 0.2 Special Drug Use Surveillance \"Long-term Use in Patients With Impaired Glucose Tolerance\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The frequency of adverse events by type, seriousness, time to onset, etc. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to Week 72"
            }, 
            {
                "description": "Estimate over time of the cumulative rate of progression to T2DM. Diagnostic criteria for T2DM are: (1) \"Blood glucose \u2265200 mg/dL at any time, morning fasting blood glucose \u2265126 mg/dL, or 2-hour post 75-g (Oral Glucose Tolerance Test) blood glucose \u2265200 mg/dL. (2) Two or more glucose measurements obtained on different days that meet the above-mentioned criteria, or (3) A single glucose measurement meeting the above-mentioned criteria if the patient meets any of the following conditions: (i) Has typical symptoms of diabetes mellitus (e.g., dry mouth, polydipsia, polyuria, weight loss) (ii) HbA1C \u22656.5% (JDS value) (iii) Obvious diabetic retinopathy", 
                "measure": "Progression to Type 2 Diabetes Mellitus (T2DM)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 72"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993927"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Estimate over time of the cumulative rate of \"IGT normalization\". IGT normalization\" will be determined by the survey physician based on the results of the 75-g oral glucose tolerance test (OGTT), glucose metabolism markers, and other data.", 
            "measure": "Normalization of Impaired Glucose Tolerance(IGT)", 
            "safety_issue": "No", 
            "time_frame": "From baseline to Week 72"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}